First Tracks Biotherapeutics Earnings
NASDAQ: TRAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
First Tracks Biotherapeutics earnings summary
In its most recent report on Nov 11, 2026 (Sep/2026), TRAX posted EPS of $-0.88 versus the $-0.92 consensus estimate, a positive surprise of 4.3%. First Tracks Biotherapeutics beat the consensus EPS estimate in 2 of the last 2 quarters, with a median surprise of +4.3%. Across the last 3 reports, TRAX shares moved an average of 5.1% (in either direction) in the first trading session after results, rising 0 times and falling 3 times.
Summary generated from market data by MetaCap's automated system. Methodology
TRAX earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Nov 11, 2026 | $-0.92 | $-0.88 | +4.3% | -11.6% |
| Nov 3, 2026 | $-0.92 | $-0.88 | +4.3% | -1.7% |
| Aug 12, 2026 | — | $-0.95 | — | -2.1% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.